جست‌وجوی استاد و پژوهشگر

Kushal Deyمشاهده پروفایل

استادیار

• Statistical Genetics
• Machine Learning in Genomics
• Functional Genomics
• +۵ مورد دیگر

Kushal Dey serves as an Assistant Professor in the Computational and Systems Biology Program at Memorial Sloan Kettering Cancer Center (MSKCC), part of the Graduate School of Medical Sciences in partnership with Weill Cornell Medicine. His research integrates statistical and machine learning approaches with genomic data to understand the regulatory architecture of complex diseases. Dr. Dey's research focuses on developing computational methods that integrate human disease genetics with functional genomics data. His work spans immune-related diseases including Alzheimer's and inflammatory bowel disease, as well as heritable cancers like breast and prostate cancer. His lab develops models to prioritize variants, genes, and cell states for disease using genetic, genomic, and perturbation data, with emphasis on causal directed graphs and benchmarking pipelines informed by disease genetics. His recent publications highlight expertise in GWAS, colocalization, spatial transcriptomics, Perturb-seq, and RNA+ATAC multiome analysis. His work frequently appears in top journals like Nature Genetics, with a focus on single-cell multi-omics approaches to understand disease mechanisms at cellular resolution. Scientific Awards: Josie Robertson Investigator (2023–2028) K99/R00 Pathway to Independence Award (NIH/NHGRI) (2022–2026) NIH/NHGRI Early Stage Investigator R01 (2025-2030) NCI P30 CCSG supplement – 'LLMs in cancer research' (2023-2024) Catalog Working Group Co-chair + Disease Focus Group Lead: IGVF consortium (2023-) Dr. Dey mentors several graduate students through the Weill Cornell Graduate School (WGS), including Thahmina Ali, Pretty Garcia, Karthik Guruvayurappan, Louis Liu, Sarthak Tiwari, Berk Turhan, and Harry Zhang. His lab has received multiple grants including the AWS IMAGINE Grant Children's Health Innovation Award 2024-2025 (as Project Co-lead) and PSRP Developmental Funds Awards (2025: Co-lead). The lab actively collaborates with consortia including ENCODE, ADSP, MorPhiC, and IGVF, maintaining strong ties with Columbia University, Stanford University, and Harvard T.H.Chan School of Public Health. The Kushal Dey Lab is part of the vibrant Tri-Institutional Research campus adjacent to Rockefeller University and Weill Cornell Medical College, offering a collaborative environment focused on computational genomics and disease mechanisms.

Maryellen L. Gigerمشاهده پروفایل

استاد

• Computer-Aided Diagnosis
• Machine Learning
• Deep Learning
• +۷ مورد دیگر

Maryellen L. Giger, Ph.D. is the A.N. Pritzker Distinguished Service Professor of Radiology, Committee on Medical Physics, and the College at the University of Chicago. She serves as Vice-Chair of Radiology (Basic Science Research) and was the immediate past Director of the CAMPEP-accredited Graduate Programs in Medical Physics/Chair of the Committee on Medical Physics. Her career spans over 30 years of pioneering research in computer-aided diagnosis, machine learning, and deep learning applications in medical imaging. Dr. Giger's research focuses on computational image-based analyses for cancer risk assessment, diagnosis, prognosis, and response to therapy, particularly in breast cancer, lung cancer, prostate cancer, lupus, bone diseases, and more recently, COVID-19. Her work has evolved from developing computer-aided diagnosis systems to utilizing 'virtual biopsies' in imaging genomics association studies for discovery. She has made significant contributions to quantitative imaging, radiomics, and AI applications in medical imaging, with emphasis on translating research into clinical practice. Her publication record shows a clear trajectory from foundational work in computer vision for medical imaging to cutting-edge AI and deep learning applications. The recent publications demonstrate her leadership in large-scale collaborative efforts like the Medical Imaging and Data Resource Center (MIDRC), focus on health equity through AI analysis, and expansion into diverse applications including gynecological imaging, lung cancer screening, and trauma assessment. Her work consistently bridges technical innovation with clinical relevance. Dr. Giger has received numerous prestigious honors including membership in the National Academy of Engineering, the William D. Coolidge Gold Medal (the highest award from AAPM), and being named one of the 50 most impactful medical physicists in the last 50 years. She is a Fellow of multiple professional societies including AAPM, AIMBE, SPIE, SBMR, and IEEE. Her 2019 TIME magazine recognition for QuantX, the first FDA-cleared machine-learning-driven system for cancer diagnosis, highlights her translational impact. As an educator and mentor, Dr. Giger has guided over 100 graduate students, residents, and medical students throughout her career. She has secured substantial research funding including NIH R01 grants and serves as contact PI for the NIH NIBIB-funded & ARPA-H-funded Medical Imaging and Data Resource Center (MIDRC). Her leadership extends to former presidencies of the American Association of Physicists in Medicine and SPIE, and she was the inaugural Editor-in-Chief of the SPIE Journal of Medical Imaging. Dr. Giger co-founded Quantitative Insights, Inc. through the University of Chicago's New Venture Challenge, which developed QuantX - the first FDA-cleared AI system for cancer diagnosis. She leads the Medical Imaging and Data Resource Center (MIDRC), a critical resource for AI development in medical imaging that received the 2023 DataWorks Prize. Her research laboratory bridges engineering, physics, and clinical medicine to develop and validate quantitative imaging biomarkers and AI tools for precision medicine.

Lambertus Kiemeneyمشاهده پروفایل

استاد

• Biobanking
• Urological cancers
• Clinical epidemiology
• +۳ مورد دیگر

Lambertus (Bart) Kiemeney is a Professor of Cancer Epidemiology and Chair of the Department for Health Evidence at Radboud University Medical Center (Radboudumc). As Scientific Director of the Radboud Institute for Health Sciences since 2012, he leads one of Radboudumc’s three major research institutes. His career spans clinical epidemiology, genetic epidemiology, and urological cancer research, with over 500 peer-reviewed publications and 25 book chapters. MSc in Biomedical Sciences (1988), PhD in Epidemiology (1992) from Radboud University Postdoctoral training at Johns Hopkins University and Fred Hutchinson Cancer Research Center (1992-1994) Kiemeney’s research focuses on the genetic and clinical epidemiology of bladder and prostate cancer , emphasizing genome-wide association studies (GWAS) and environmental risk factors. His work has identified key genetic loci (e.g., FGFR3, SLC14A1) and challenged assumptions about hereditary cancer screening and biomarker validity. Publications highlight his leadership in genetic epidemiology , including the first bladder cancer GWAS (2008) and large-scale replication studies (2014-2016). Trends include mechanistic research on urine concentration effects (2011), antioxidant risk factors (2012), and clinical translation of biomarkers (2015). Scientific Awards: 2014: Thomson Reuters’ “World’s Most Influential Scientific Minds” 2013: Dominique Chopin Distinguished Researcher Award (ESUR) 2012: Eminent Scholar at COMSATS Institute 2003-2004 & 2002: Multiple “Lecturer of the Year” awards 1992: Netherlands Cancer Society Fellowship 1983-1988: Cum Laude degrees in Physiotherapy and Biomedical Sciences As coordinator of the EU 7th Framework Programme project on renal cell cancer, Kiemeney has shaped international research collaborations. His work on coal tar safety (2010) resolved long-standing clinical concerns in dermatology.

XiuJun Liمشاهده پروفایل

استاد

• Microfluidics
• Nanotechnology
• Lab-on-a-Chip
• +۹ مورد دیگر

Dr. XiuJun Li is a Professor in the Department of Chemistry and Biochemistry at The University of Texas at El Paso (UTEP) within the College of Science. He leads the Li Microfluidic Lab-on-a-Chip & Nanotechnology Group, focusing on the development of cutting-edge, low-cost diagnostic technologies for applications in bioanalysis, biomedical engineering, forensic science, and environmental science. His work is highly interdisciplinary, bridging chemistry, engineering, and biology. Dr. Li's primary research interests lie in microfluidics, nanotechnology, lab-on-a-chip systems, and point-of-care diagnostics. His lab specializes in creating paper and polymer hybrid microfluidic devices for the ultrasensitive detection of cancer biomarkers, infectious diseases (such as SARS-CoV-2 and pertussis), and environmental toxins. A significant focus is on making these devices instrument-free and affordable, particularly for use in resource-limited settings and rural areas. His recent work on a $3 paper-based cancer detector has garnered significant media attention, including features in the New York Post and local TV stations. The trend in Dr. Li's recent publications reveals a strong emphasis on developing portable, visual, and quantitative diagnostic platforms. His research frequently involves the integration of nanomaterials for signal amplification, the use of microfluidic chips for controlled reactions, and innovative readout methods like bar-chart displays and smartphone-based detection, all aimed at creating practical tools for real-world healthcare challenges. Dr. Li has received substantial recognition for his contributions to science, including being named one of the World's Top 2% of Cited Researchers by Elsevier and a Top Scholar by ScholarGPS. He is an Editorial Board Member for Microsystems & Nanoengineering (Nature Publishing Group) and has been awarded a Travel Grant from GEM on the Road’s PFI Programming. He holds patents for his inventions in biosensing and photothermal detection. Dr. Li is a dedicated mentor and educator. He has advised numerous PhD and Master's students, many of whom have gone on to prestigious postdoctoral positions at institutions like Harvard, UPenn, and MD Anderson. He is also the Director of the Forensic Science program at UTEP, where he organizes outreach events to engage students. His lab is actively involved in research, with multiple postdoctoral fellows and graduate students currently working on projects related to cancer detection and infectious disease study.

• Tumor Glycocalyx Targeting
• Protease-Activated Anticancer Prodrugs
• Cancer Drug Development
• +۴ مورد دیگر

Robert Falconer serves as Professor of Medicinal Chemistry and Director of the Institute of Cancer Therapeutics (ICT) at the University of Bradford. A registered pharmacist with the General Pharmaceutical Council, he leads a multidisciplinary research team focused on tumor glycocalyx targeting and protease-activated anticancer prodrugs. His academic journey spans from pharmacy training at The School of Pharmacy, University of London to establishing the medicinal chemistry program at ICT in 2005. Pharmacy Degree: The School of Pharmacy, University of London (now UCL School of Pharmacy) PhD in Medicinal Chemistry: London (2000) Professional Registration: General Pharmaceutical Council Professor Falconer's research centers on tumor glycocalyx modulation through polysialyltransferase inhibition and protease-activated drug delivery systems. His work spans osteosarcoma, neuroblastoma, breast, and prostate cancers with emphasis on developing targeted therapies that minimize systemic toxicity. The Falconer group employs computational design, solid-phase synthesis, and advanced biological evaluation techniques to develop novel anticancer agents. His publication portfolio demonstrates consistent focus on tumor-specific activation mechanisms (2023-2025), glycocalyx-targeted metastasis inhibition (2019-2021), and prodrug development (2010-2014). Recent work emphasizes theranostic applications and DNA repair targeting for pediatric cancers. Fellow of the Royal Society of Chemistry Former Honorary Treasurer, RSC Central Yorkshire Local Section Trust (2012-2018) Registered Pharmacist with General Pharmaceutical Council As principal investigator, Falconer has secured substantial funding from Breast Cancer Now, Bone Cancer Research Trust, Worldwide Cancer Research, and Neuroblastoma UK. He leads the £2m ICT Doctoral Training Centre and co-founded spin-out company Incanthera plc, which is advancing the MMP-targeted prodrug ICT2588 to clinical trials. His mentorship includes three PhD students and multiple postdoctoral researchers developing next-generation cancer therapeutics. The Falconer group operates within the ICT's state-of-the-art facilities, collaborating with Stanford University, University of Sheffield, and Ellipses Pharma. Current projects address unmet needs in pediatric oncology while developing platform technologies applicable across multiple cancer types.

• Cancer Epidemiology
• Breast Cancer
• Reproductive Epidemiology
• +۳ مورد دیگر

Anna Johansson is an Assistant Professor at the Karolinska Institutet , leading research in cancer epidemiology and biostatistics at the Department of Medical Epidemiology and Biostatistics . She serves as a Docent and group leader, with affiliations at Karolinska University Hospital, Capio St Göran Hospital, and Uppsala University Hospital. Research Interests: Her work spans Cancer epidemiology with focus on breast cancer Reproductive factors and cancer risk Socioeconomic inequalities in healthcare Applied biostatistics and register-based methods Nordic cross-country collaborations Recent Article Trends show emphases on Nordic cancer survival comparisons Pregnancy-associated cancer outcomes Stage-specific mortality analysis Impact of healthcare disruptions Statistical methods for registry data Fertility preservation in oncology Scientific Awards Senior Investigator Award, Swedish Cancer Society Teaching & Mentorship includes survival analysis, epidemiological designs, and data management workshops within the Karolinska Doctoral Programme. She supervises PhD students in cancer and reproductive epidemiology. Collaborative Networks extend to the Nordic Cancer Union, Cancer Registry of Norway, and clinical research teams across Sweden and the Nordic region.

Vincenzo Abbateمشاهده پروفایل

مدرس ارشد

• Analytical Toxicology
• Forensic Chemistry
• Metal Chelators
• +۶ مورد دیگر

Dr Vincenzo Abbate is a Senior Lecturer in Bioanalysis at King's College London , affiliated with the Faculty of Life Sciences & Medicine and serving as Programme Director for the MSc in Analytical Toxicology . He holds a Pharm.D. (2004, Federico II University of Naples) and a PhD in Chemistry and Analytical Sciences (2008, The Open University) . Prominent research themes include: Metal Chelators for Medical/Diagnostic Applications New Psychoactive Substances (NPS) Toxicology Forensic Drug Analysis Nuclear Medicine Radiotracers Recent publications highlight advancements in nanoneedles for lipidomics , thallium-based radiopharmaceuticals , and stability studies of synthetic cathinones , with a focus on interdisciplinary collaborations across bioanalysis, synthetic chemistry, and clinical translational research . Scientific Recognition : Maplethorpe Fellowship (2008) Chartered Chemist (CChem) and Chartered Scientist (CSci) President of IUPAC Subcommittee on Toxicology and Risk Assessment His grants and projects include BBSRC , MRC , and Parkinson’s UK funding, with industrial partnerships like Theragnostics Ltd and TicTac Communications . He leads a team of 10 researchers and is actively involved in Spatial Biology Network and Multiscale Biofilm Research Hub initiatives.

Kequan Zhouمشاهده پروفایل

استاد

• Nutraceuticals
• Functional Foods
• Bioactive Food Components
• +۶ مورد دیگر

Kequan Zhou is a Professor in the Department of Nutrition and Food Science at Wayne State University's College of Liberal Arts and Sciences. His research focuses on value-added nutraceuticals and functional foods for chronic disease prevention, particularly targeting Type 2 diabetes and obesity through bioactive food components. Supported by NIH, USDA, and NSF grants, Zhou leads studies on gut microbiota interactions, enzyme inhibition, and antioxidant mechanisms. Ph.D. in Food Science, University of Maryland-College Park (2005) M.S. in Public Health, China CDC (2001) M.D. in Clinical Medicine, Shandong University (1998) Zhou's recent work explores probiotic bacteria like Akkermansia muciniphila, marine-derived antimicrobials, and grape pomace compounds. His publications span food chemistry, diabetes research, and microbiome science, with methodological innovations in enzyme immobilization and metabolite characterization. Scientific Awards 2016 - Career Development Chair Award, Wayne State University 2012 - Finalist, ACS Young Scientist Award 2010 - University Research Grant Award As a Scientific Editor for the Journal of Food Science, Zhou contributes to academic leadership while teaching graduate courses in nutrition, food safety, and functional foods. His interdisciplinary approach bridges food science, pharmacology, and public health.

Wei Shaoمشاهده پروفایل

استادیار

• Medical Imaging
• Artificial Intelligence
• Machine Learning
• +۳ مورد دیگر

Dr. Wei Shao is an Assistant Professor in the College of Medicine at the University of Florida, specializing in artificial intelligence applications in medical imaging. His work focuses on developing machine learning algorithms for medical image registration, segmentation, and diagnosis, with a particular emphasis on integrating these tools into clinical workflows. Dr. Shao holds a Ph.D. in Electrical and Computer Engineering from Stanford University (2022), preceded by M.S. degrees in Mathematics and Electrical and Computer Engineering from the University of Iowa (2019-2018). His postdoctoral training focused on deep learning and medical imaging. His research projects include: Machine learning algorithms for multimodal image registration and segmentation AI-driven disease diagnosis on medical images Integrating image processing into clinical practices Notable contributions include advancements in 3D medical image segmentation, text-guided models for radiology, and AI-enhanced micro-ultrasound for prostate cancer screening. His work bridges computational methods with clinical needs, aiming to improve diagnostic accuracy and patient care. Recent publications highlight innovations in diffusion models, vision-language integration for medical imaging, and robust artifact detection in 4DCT scans. These studies underscore his commitment to advancing AI-driven solutions in healthcare.

Anand Krishnanمشاهده پروفایل

استادیار

• Nerve-tumor interface
• Nerve regeneration
• Cancer biology
• +۵ مورد دیگر

Dr. Anand Krishnan serves as Assistant Professor in the Department of Anatomy, Physiology and Pharmacology at the University of Saskatchewan's College of Medicine, where he leads research on nerve-tumor interfaces and neural macrophage biology. His work bridges neuroscience and oncology to identify therapeutic targets for cancer and neurodegenerative disorders. Education: Postdoctoral Fellow, Division of Neurology, University of Alberta, Canada Postdoctoral Fellow, Clinical Neurosciences, University of Calgary, Canada PhD in Biotechnology (Cancer Biology), Rajiv Gandhi Centre for Biotechnology, India Master of Pharmacy (Pharmacology), Manipal University, India Pharma R&D Experience: Orchid Chemicals and Pharmaceuticals Limited; Alembic Pharmaceuticals Limited Dr. Krishnan's research program investigates two core areas: molecular mapping of tumor-nerve interfaces to uncover novel therapeutic targets, and defining the roles of self-renewing resident macrophages in nervous system homeostasis and disease. His lab employs proteomics, murine models, and in vitro neuronal cultures to explore how tumors and nerves mutually support growth through neural invasion and autonomic signaling. Analysis of his 2020-2024 publications reveals consistent focus on neuro-oncology mechanisms, particularly peripheral nerve regeneration pathways (Myc interactome, growth-primed DRG), tumor-nerve crosstalk (sympathetic signaling in prostate cancer), and neurodegenerative targets (MANF). Key methodologies include comparative proteomics, molecular mapping, and drug repurposing screens. Research Funding: Natural Sciences and Engineering Research Council (NSERC) Cancer Research Society (CRS) CIHR Institute of Cancer Research Breast Cancer Society of Canada (BCSC) Prostate Cancer Fight Foundation (PCFF) & Ride for Dad Saskatchewan Health Research Foundation (SHRF) College of Medicine Research Award (CoMRAD) CoMBRIDGE Fund Start-up Research Fund Based at Saskatoon City Hospital within the Cameco MS Neuroscience Research Centre, the Krishnan Lab trains students supported by NSERC USRA, Dean's project fellowships, OVDR Biomedical research fellowships, and Mitacs awards. The lab's strategic location adjacent to the Meewasin Valley provides collaborative opportunities for translational neuroscience research focused on nerve regeneration and cancer therapeutics.

• Genetic Engineering
• Immunology
• Oncology
• +۵ مورد دیگر

William A. Nyberg is an Assistant Professor at the Department of Medicine, Huddinge, Karolinska Institutet. His research focuses on the in vivo genetic modification of T cells for cancer treatment, utilizing chimeric antigen receptors (CARs), CRISPR/Cas9, and synthetic vectors like adeno-associated viruses (AAVs) and lipid nanoparticles (LNPs). The lab aims to eliminate time-consuming ex vivo manufacturing processes and enhance CAR-T cell efficacy in immunosuppressive tumor microenvironments. Assistant Professor, Department of Medicine, Huddinge (2024–2030) SciLifeLab Fellow (2024–2030) European Research Council grant recipient (2025–2029) Recruiting postdoctoral fellows, doctoral, and master's students His work intersects Genetic Engineering, Immunology, and Oncology, with key subfields including CAR-T cell therapy, CRISPR/Cas9, tumor microenvironment, and synthetic biology. Collaborative projects involve Yenan Bryceson's group and translational humanized/syngeneic mouse models. Scientific Awards: SciLifeLab Fellow (Karolinska Institute, 2024–2030) Advising: Julian Fischbach (Doctoral student)

Elizabeth Lipkeمشاهده پروفایل

استاد

• Tissue Engineering
• Cancer Research
• Cardiac Tissue Engineering
• +۵ مورد دیگر

Dr. Elizabeth Lipke is the Mary and John H. Sanders Professor of Chemical Engineering at Auburn University’s Samuel Ginn College of Engineering. Her lab focuses on tissue engineering, particularly in cancer and cardiovascular systems, with a focus on 3D in vitro models for drug screening and disease mechanisms. She leads interdisciplinary research combining biomaterials, microfluidics, and stem cell technologies to model complex biological systems. Education & Affiliations: PhD in Chemical Engineering (assumed based on role) Director of the Lipke Lab at Auburn University Collaborator with Dr. Arnold (cancer biology) and Dr. Mistriotis (biomedical engineering) Research Interests: Engineered cancer models to study obesity-related colorectal cancer progression Cardiac tissue engineering using pluripotent stem cells Microfluidic platforms for scalable production of hydrogel microspheres Drug efficacy testing in vascularized tumor models Awards & Recognition: 2024 AIMBE College of Fellows Inductee (top 2% in medical/biological engineering) NSF Grant ($621,934) for cardiac tissue manufacturing research (2018) Alabama Launchpad $25,000 award for Vivosphere technology (2023) Lab Highlights: Developed tumor-mimetic microvascular platforms for anti-cancer drug screening Engineered insulin-sensitive/insulin-resistant colorectal cancer models Pioneered scalable production of cardiac tissue microspheres from hiPSCs Grants & Funding: NSF RECODE Grant (2021) LAUNCH Innovation Grant (2023) Labs/Teams: Lipke Lab at Auburn University Collaborations with Arnold Lab (cancer biology) and Mistriotis Lab (biomedical engineering)

Abhijit Patelمشاهده پروفایل

دانشیار

• Liquid Biopsy
• Circulating Tumor DNA
• Cancer Detection
• +۶ مورد دیگر

Abhijit Patel, MD, PhD is an Associate Professor of Therapeutic Radiology at Yale School of Medicine and serves as the Medical Director of the Lawrence & Memorial Cancer Care Center in Waterford. His work focuses on developing innovative liquid biopsy approaches for cancer detection and monitoring, with particular emphasis on circulating tumor DNA analysis. Dr. Patel received his medical education at Yale University School of Medicine (MD, 2003) and completed his PhD in Molecular Biophysics and Biochemistry from Yale University Graduate School (2002). His training includes an internship at Memorial Sloan-Kettering Cancer Center (2004), residency in Radiation Oncology at Harvard Medical School (2008), and postdoctoral research at the Howard Hughes Medical Institute, Massachusetts General Hospital (2008). His research program centers on developing ultrasensitive diagnostic tools to measure trace amounts of circulating tumor DNA molecules through analysis of genomic and epigenomic signatures. Dr. Patel's work addresses key challenges in liquid biopsy technology, including assay development for circulating tumor DNA detection, high-throughput RNA profiling, and clinical applications for early cancer detection, treatment response assessment, and monitoring treatment resistance. His research draws upon expertise from clinical oncology, molecular biology, chemistry, computer science, and microfluidics. Analysis of Dr. Patel's recent publications reveals a strong focus on advancing liquid biopsy technologies for cancer detection and monitoring. His work spans technical innovations in DNA sequencing and analysis, clinical validation studies across multiple cancer types (particularly lung cancer), and collaborative efforts through the Liquid Biopsy Consortium to address challenges in early cancer detection. His research consistently aims to bridge the gap between molecular diagnostics and clinical oncology practice. Lungevity Foundation Early Detection Award (2015) Tina's Wish Foundation Research Award (2015) ASTRO Junior Faculty Career Research Training Award (2011) Brozman Foundation Fellowship (2011) American Cancer Society Institutional Research Grant (2010) Dr. Patel serves as a sub-investigator on multiple clinical trials focused on cancer detection and treatment, including studies on adjuvant radiotherapy for head and neck cancer, mechanisms of treatment resistance in lung cancer, and peripheral blood profiling for lung cancer screening. He leads the Patel Lab at Yale, which collaborates extensively with scientists and clinicians across disciplines to advance liquid biopsy technologies for clinical implementation.

• Geriatric Psychiatry
• Aging
• Health Sciences
• +۶ مورد دیگر

Øyvind Kirkevold is a Professor at the Department of Health Sciences Gjøvik at the Norwegian University of Science and Technology (NTNU). He also holds research roles at the National Center for Aging and Health at Vestfold Hospital HF and the Department of Geriatric Psychiatry at Innlandet Hospital HF. Research interests include geriatric psychiatry, aging, dementia, physical performance in older adults, home care service interventions, and resource planning in healthcare. His work emphasizes qualitative methodologies, geriatric assessment, and improving care for frail elderly populations. Recent publications focus on meaning in life for dementia patients, physical performance in prostate cancer survivors, crisis prevention for frail individuals, geriatric assessment interventions, and resource planning using the Nursing Activities Score. These studies span geriatric psychiatry, oncology, and healthcare logistics. Scientific awards : 2012 - Andrus Viidik Prize 2004 - Leon Jarner Research Prize Projects include active initiatives like screening for delirium, assessing consent capacity, prostate surgery outcomes, and completed projects on minority elder care. He collaborates with institutions such as Innlandet Hospital HF, Oslo University Hospital, and the National Center for Aging and Health.

ANDREA KASINSKIمشاهده پروفایل

استاد

• Non-coding RNA biology
• MicroRNA therapeutics
• Cancer epigenetics
• +۳ مورد دیگر

Andrea Kasinski is a Professor of Biological Sciences and Deputy Director of the Purdue Institute for Cancer Research at Purdue University. Her research focuses on non-coding RNAs (microRNAs, lncRNAs, circRNAs) in cancer development and their therapeutic applications. She leads a multidisciplinary team investigating RNA delivery systems, extracellular vesicle biology, and epigenetic regulation in cancer. Key projects include ligand-mediated delivery of miRNAs, exosome-based therapies, and high-throughput screens for miRNA inhibitors. Education: PhD in Molecular & Systems Pharmacology (Emory University, 2009), Postdoctoral Fellowship in Genetics (Yale University, 2013). Awards include NIH Pathway to Independence Award (2013), American Cancer Society Research Scholar (2017), and multiple grants from NIH/NCI (R01 CA205420, R01 CA226259). Her lab has pioneered 'FolamiRs' – folate-targeted miRNA therapeutics – and developed novel strategies for endosomal escape of RNA payloads. Major contributions include identifying miRNA drivers of drug resistance, demonstrating exosome-mediated tumor progression, and advancing miR-34a as a clinical candidate. The lab maintains active collaborations with institutions including Harvard Medical School, MD Anderson Cancer Center, and the National Cancer Institute. Current initiatives focus on KMT5C-mediated epigenetic regulation in EGFR-resistant lung cancers and translational development of fully modified miR-34a (FM-miR-34a).